Brief: Carisma Therapeutics Says First CT-0525 Patient Expected To Be Treated In First Half Of 2024
28/11/2023 12:36
Nov 28 (Reuters) - Carisma Therapeutics Inc CARM.O :
* CARISMA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND
APPLICATION
FOR CT-0525, A NOVEL HER2-TARGETING CAR-MONOCYTE
* CARISMA THERAPEUTICS INC: FIRST PATIENT EXPECTED TO BE
TREATED
IN FIRST HALF OF 2024
Source text for Eikon: ID:nPn7llNKla
Further company coverage: CARM.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Carisma Therapeutics
See all newsBrief: Carisma Therapeutics & Modernatx Amend Collaboration & And License Agreement - SEC Filing
Carisma Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Carisma Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Carisma Therapeutics And Orthocellix Enter Into Definitive Merger Agreement
Carisma Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary